In this issue:
Measure Up 1 and 2 demonstrate efficacy and safety of upadacitinib
AD Up: upadacitinib safe and efficacious in combination with corticosteroids
Bacteriotherapy may be a novel therapeutic for AD
Delgocitinib ointment elicits improvements in paediatric patients
Recommendations for vaccination for paediatric patients receiving dupilumab
Nemolizumab elicits rapid improvement in itch, sleep and skin lesions
Stem cell transplant and dupilumab for DOCK8 deficiency-related dermatitis
Dupilumab shows efficacy in prurigo nodularis-like AD
Significantly increased risk for conjunctivitis in AD
Baricitinib confers benefits in itch and sleep as quickly as 24 hours after the first dose
Please login below to download this issue (PDF)